Chester County News and Community Website
DOYLESTOWN, PA — Hatch BioFund has invested in Optimeos Life Sciences, a Princeton University spinout developing a nanoparticle platform for delivering gene therapies and other biologic medicines, expanding the Pennsylvania …
Hatch BioFund Invests in Gene Delivery Startup Optimeos Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration has expanded approval of the gene therapy Casgevy to include children as young as 2 with sickle cell disease or transfusion-dependent …
FDA Expands Casgevy Approval to Children as Young as 2 Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration has released draft guidance that could shorten development timelines for gene therapies by allowing drugmakers to make greater use of existing …
FDA Issues Gene Therapy Guidance Aimed at Faster Reviews Read More
PHILADELPHIA, PA — iECURE announced that new clinical data from its ongoing OTC-HOPE trial evaluating ECUR-506 in neonatal-onset ornithine transcarbamylase deficiency will be presented this month at two medical conferences.
iECURE Reports Early OTC Gene Therapy Trial Results Read More
PHILADELPHIA, PA — Latus Bio said it will present new preclinical and computational data related to experimental gene therapies for Huntington’s disease and CLN2 disease at the ASGCT 2026 Annual …
Latus Bio to Present Gene Therapy Data at ASGCT Read More
WASHINGTON, D.C. — Federal regulators are advancing new safety standards for gene-editing therapies, aiming to speed development of treatments for rare and previously incurable diseases while tightening oversight of potential …
FDA Moves to Fast-Track Gene Editing Safety Standards Read More
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has completed enrollment and dosing in its Phase 2/3 clinical trial evaluating a gene therapy candidate for Stargardt disease.
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial Read More
WASHINGTON, D.C. — Children with a life-threatening immune disorder now have a new treatment option following federal approval of the first gene therapy designed to correct the underlying cause of …
FDA Approves First Gene Therapy for Rare Childhood Immune Disorder Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced it has completed enrollment for the Phase 3 liMeliGhT clinical trial evaluating OCU400, a gene therapy candidate for retinitis pigmentosa, a group …
Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy Read More WASHINGTON, D.C. — The U.S. Food and Drug Administration signaled a sweeping shift in how cutting-edge therapies reach patients this month, unveiling regulatory flexibility for cell and gene therapies, modernizing …
FDA Clears Faster Path for Gene Cures as Rare Disease Breakthrough Arrives Read More